Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference
BURLINGTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at Needham &
View HTML
Toggle Summary Flexion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Early launch activities for ZILRETTA ® progressing well (strong clinical interest from prescribers; broad coverage from payers; encouraging feedback from patients)    Company booked net ZILRETTA sales of approximately $355K in Q4 Encouraging initial results from repeat administration trial of
View HTML
Toggle Summary Flexion Therapeutics to Present at the Cowen 38th Annual Health Care Conference
BURLINGTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will be presenting at the Cowen 38th Annual Health Care Conference in Boston, Massachusetts. Michael Clayman, M.D., President and Chief Executive Officer, is scheduled to present at 10:40 a.m.
View HTML
Toggle Summary Flexion Therapeutics Presents Clinical Data at AAOS 2018 Annual Meeting and the American Pain Society Annual Scientific Meeting
Post-hoc analysis demonstrates potential of ZILRETTA ®  (triamcinolone acetonide extended-release injectable suspension) to provide effective pain relief regardless of prior intra-articular corticosteroid use Effects of ZILRETTA show improvement on health-related quality of life in patients with
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to two new employees for an aggregate of 4,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an
View HTML
Toggle Summary Flexion Therapeutics to Present at the 39th Annual Raymond James Institutional Investors Conference
BURLINGTON, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Raymond James 39 th Annual Institutional Investors Conference in Orlando, Florida. Dr.
View HTML
Toggle Summary Flexion Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 8, 2018
BURLINGTON, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth quarter and full year 2017 financial results after the close of the U.S. financial markets on Thursday, March 8, 2018.
View HTML
Toggle Summary Flexion Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
BURLINGTON, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at the RBC Capital
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to six new employees for an aggregate of 38,800 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an
View HTML
Toggle Summary Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)
Data show that 95% of patients achieved clinical benefit after a single administration of ZILRETTA To date, 90% of eligible patients received a second administration between Weeks 12 and 24 BURLINGTON, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.
View HTML